Novartis (NVS) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positive opinion and recommended granting marketing authorization for Kisqali for the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer, EBC, at high risk of disease recurrence, including those with node-negative disease.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Election 2024: Where To Put Your Money Ahead of the Vote
- On drug prices, Harris pushes for cuts, Trump offers few specifics, NYTimes say
- LLY, NVS, or ISRG: Which Healthcare Stock Scores Wall Street’s “Strong Buy” Rating?
- Trump backs off support of controversial drug pricing plan, STAT reports
- Pfizer withdrawal of Oxbryta raises questions, sends Fulcrum stock higher